PT  - JOURNAL ARTICLE
AU  - Cunningham, Muriel
ED  - Fischer, Kathelijn
TI  - Recombinant Human Coagulation Factor IX Fc Fusion Protein Effective in Kids B-LONG Study
DP  - 2015 Sep 10
TA  - MD Conference Express
PG  - 6--7
VI  - 15
IP  - 21
4099  - http://mdc.sagepub.com/content/15/21/6.2.short
4100  - http://mdc.sagepub.com/content/15/21/6.2.full
AB  - The Kids B-LONG study was conducted to evaluate the pharmacokinetics, safety, and efficacy of recombinant human coagulation factor IX Fc fusion protein (rFIXFc) in pediatric subjects with hemophilia B. rFIXFc is considered safe and efficacious for prophylaxis and the control of acute bleeding in children age < 12 years.